Notice of Results

In brief · summary, not quotable

Oxford BioDynamics Plc has announced that it expects to release its results for the year ended 30 September 2025 on Tuesday, 16 December 2025. The company, which specializes in precision clinical diagnostics using its EpiSwitch® 3D genomics platform, currently offers two commercial products: the EpiSwitch® PSE for prostate cancer screening and the EpiSwitch® CiRT for predicting response to immuno-oncology treatments.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your OBD notes

Oxford, UK - 9 December 2025 - Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, expects to announce its results for the year ended 30 September 2025 on Tuesday 16 December 2025.

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.

Highlight & share

Select text in the announcement to share it as a quote – or sign in to save highlights and notes.

Oxford Biodynamics OBD · £16m

Company page →

Share price

−1.9% on the day

−61.5% since · 0.1p on 9 Oct 2026

Oxford Biodynamics – more announcements

26 Jan Directorate Change
22 Dec Publication of 2025 Annual Report
16 Dec Preliminary Results and Notice of AGM
22 Oct Fundraising, Posting of Circular & Notice of GM
14 Oct OBD in New Report on NHS Prostate Cancer Screening
8 Oct OBD and UEA develop test for Chronic Fatigue

All OBD announcements →